



## Toxoplasma IgM ELISA Test Kit

An enzyme immunoassay (ELISA) for the qualitative detection of IgM antibodies to *Toxoplasma* in human serum or plasma.

**IVD** For *in vitro* diagnostic and professional use only.



### INTENDED USE

The Toxo IgM assay is an enzyme-linked immunosorbent assay (ELISA) for the *in vitro* qualitative determination of IgM antibodies to *Toxoplasma gondii* in Human serum and plasma.

### INTRODUCTION

*Toxoplasma gondii* is the causative agent of Toxoplasmosis. It is an obligate intracellular protozoan parasite that has been found in many species of birds, reptiles and mammals. The organism can be transmitted through organ transplantation, transfusion of blood and leukocyte, contact with contaminated cat feces, and ingestion of rare or raw meats.

In adults, infection is usually benign or asymptomatic. However, symptomatic cases including fatal cases do occur in immunosuppressed patients who has clinical or laboratory evidence of damage to the central nervous system. In children, the risk of fetal infection vary according to the time of pregnancy when the mother becomes infected. Maternal infections occurring during the first trimester is less likely to pass infection to the fetus, however, if transmission occurs, severe outcomes such as spontaneous abortion and hydrocephalus are more likely. Infections acquired later in pregnancy, where most fetal transmissions occur, tends to cause less severe, but nonetheless serious congenital manifestations including cerebral calcifications and learning disabilities. After infection, IgM antibodies appear as early as 5 days and decrease to low levels within a few weeks or months. IgG antibodies generally appear 1-2 weeks after infection, reaching peak levels in 6-10 weeks persisting for life.

The Toxoplasma IgM ELISA Test Kit is an immunoassay for the qualitative detection of the presence of IgM antibodies to *Toxoplasma gondii* in serum or plasma specimen. The test utilizes recombinant *Toxoplasma gondii* antigens to selectively detect IgM antibodies to Toxoplasma in serum or plasma.

### PRINCIPLE

Capture method. Total duration of assay: **70 minutes**.

This kit uses capture ELISA principle to detect Toxo IgM. Polystyrene microwell strips are pre-coated with mouse anti-human IgM (anti- $\mu$  chain specific). During the first incubation step, all IgM antibodies binds to mouse anti-human IgM monoclonal antibody coated in microplate including the Anti-Toxo IgM, the wells are washed to remove unbound serum proteins, and Toxo antigens conjugated to the enzyme horseradish peroxidase (HRP-Conjugate) are added. During the second incubation step, if there is Toxo IgM antibody in sample, HRP- conjugated antigens will be bound to the anti-human Toxo IgM complexes previously formed and the unbound HRP-conjugate is then removed by washing. Substrate solution is then added and catalyzed by this complex, resulting in a chromogenic reaction. The resulting chromogenic reaction is measured as absorbance. The amount of color intensity can be measured and it is proportional to the amount of antibody captured in the wells, and to the amount of antibody in the sample respectively.

### MATERIALS

#### MATERIALS PROVIDED

- **Coated Microplate**, 8x12 strips, 96 wells. Pre-coated.
- **Enzyme Conjugate**, (Red Cap) 1x11 mL/vial of HRP (horseradish peroxidase) labeled Toxo antigens in Tris-NaCl buffer containing BSA (bovine serum albumin). Contains 0.1% ProClin300 preservative.

- **Sample Diluent**, (White Cap) 1x11 mL/vial. Ready to use.
- **Positive Control**, (Red Cap) 1x0.2 mL/vial.
- **Negative Control**, (Blue Cap) 1x0.2 mL/vial.
- **Wash Buffer**, (Transparent Cap) 1x25 mL/vial, (40X concentrated), PBS-Tween wash solution.
- **Substrate**, (Brown Cap) 1x11 mL/vial. Ready to use, (tetramethylbenzidine) TMB.
- **Stop Solution**, (Yellow Cap) 1x6 mL/vial of 1 mol/L sulfuric acid.
- **Plate Lid: 2 Pieces**.
- **One package insert**.

#### MATERIALS NEEDED BUT NOT PROVIDED

- Microplate reader with 450nm and 620nm wavelength absorbent capability.
- Microplate washer.
- Incubator.
- Plate shaker.
- Micropipettes and multichannel micropipettes delivering 50 $\mu$ L with a precision of better than 1.5%.
- Absorbent paper.
- Distilled water

#### PRECAUTIONS

- For *in vitro* diagnostic use only.
- Exercise the normal precautions required for handling all laboratory reagents.
- Disposal of all waste material should be in accordance with local guidelines.
- Do not use reagents beyond the labeled expiry date.
- Do not mix or use components from kits with different batch codes.
- All the specimen and reaction wastes should be considered potentially biohazard. The handling of specimens and reaction wastes should be in accordance with the local regulations and guidelines.
- The Stop Solution contains sulfuric acid, which can cause severe burns. In the event of contact with eyes, rinse immediately with plenty of water and seek medical advice.
- Neutralized acids and other liquid waste should be decontaminated by adding a sufficient volume of sodium hypochlorite to obtain a final concentration of at least 1.0%. Exposure to 1.0% sodium hypochlorite for 30 minutes may be necessary to ensure effective decontamination.
- Some reagents contain 0.05% or 0.1% ProClin 300 which may cause sensitization by skin contact, which must therefore be avoided. Reagents and their containers must be disposed of safely. If swallowed, seek medical advice immediately and show this container or label.
- Substrate has an irritant effect on skin and mucosa. In case of possible contact, wash eyes with an abundant volume of water and skin with soap and abundant water. Wash contaminated objects before reusing them. If inhaled, take the person to open air.
- For information on hazardous substances included in the kit please refer to the Materials Safety Data Sheet (MSDS), which is available on request.
- Do not smoke, drink, eat or apply cosmetics in the work area.
- Do not pipette by mouth. Wear protective clothing, disposable gloves and eye/ face protection when handling samples and reagents. Wash hands after use.
- If any of the reagents comes into contact with the skin or eyes, wash the area extensively with water.

#### STORAGE AND STABILITY

- Store at 2-8°C.
- Seal and return all the other unused reagents to 2-8 °C, under which conditions the stability will be retained for 2 months, or until the labeled expiry date, whichever is earlier.

#### SPECIMEN COLLECTION AND PREPARATION

- Human serum or plasma is recommended for this assay.
- Cap and store the samples at 18-25 °C for no more than 8 hours. Stable for 7 days at 2-8°C, and 1 month at -20°C. Freeze only once.
- Do not use heat-inactivated samples.
- Sediments and suspended solids in samples may interfere with the test result which should be removed by centrifugation. Ensure that complete clot formation in serum samples has taken place prior to centrifugation.
- Avoid grossly hemolytic, lipemic or turbid samples.

#### Wash solution (40X dilution)

Add deionized water to the 40X concentrated Wash Solution Concentrate. Dilute 25 mL of Wash Solution Concentrate with 975 mL of deionized water to a final volume of 1000 mL. Stable for 2 months at room temperature.

#### PROCEDURE

Ensure the patients' samples, calibrators, and controls are at ambient temperature (18-25 °C) before measurement. Mix all reagents through gently inverting prior to use.

- **Preparation:** Mark two wells as Negative control (e.g. B1, C1), two wells as Positive control (e.g. D1, E1) and one Blank (e.g. A1, neither samples nor HRP-Conjugate should be added into the Blank well). If the results will be determined by using dual wavelength plate reader, the requirement for use of Blank well could be omitted. Use only number of strips required for the test.
- **Adding Sample Diluent:** Add **100  $\mu$ L** of Sample Diluent into their respective wells except the Blank.
- **Adding Sample:** Add **10  $\mu$ L** of Positive control, Negative control, and Specimen into their respective wells except the Blank. Mix by tapping the plate gently. Use a separate disposal pipette tip for each specimen to avoid cross-contamination.  
**Note: After adding Sample, the reagents in wells turns Blue color from Green.**
- **Incubating:** Cover the plate with the plate cover and incubate for **30 minutes at 37°C**.
- **Washing:** At the end of the incubation, remove and discard the plate cover. Wash each well **5 times** with diluted Wash Buffer. Each time allow the microwells to soak for **30-60 seconds**. After the final washing cycle, turn down the plate onto blotting paper or clean towel and tap it to remove any remainders.
- **Adding Conjugate:** Add **100 $\mu$ L** of HRP-Conjugate into each well except the Blank.
- **Incubating:** Cover the plate with the plate cover and incubate for **30 minutes at 37°C**.
- **Washing:** At the end of the incubation, remove and discard the plate cover. Wash each well **5 times** with diluted Wash Buffer. Each time allow the microwells to soak for **30-60 seconds**. After the final washing cycle, turn down the plate onto blotting paper or clean towel and tap it to remove any remainders.
- **Coloring:** Add **100  $\mu$ L** of TMB Substrate into each well including the Blank. Incubate the plate at **Room Temperature for 10 minutes avoiding light**. The enzymatic reaction between the TMB substrate and the HRP-Conjugate produces blue color in Positive control and in Toxo IgM positive sample wells.
- **Stopping Reaction:** Using a multichannel pipette or manually, add **50  $\mu$ L** of Stop Solution into each well and mix gently. Intensive yellow color develops in Positive control and Toxo IgM positive sample wells.
- **Measuring the Absorbance:** Calibrate the plate reader with the Blank well and read the absorbance at 450nm. If a dual filter instrument is used, set the reference wavelength at 630nm. Calculate the Cut-off value and evaluate the results. (Note: read the absorbance within 10 minutes after stopping the reaction).

#### QUALITY CONTROL AND CALCULATION

- Read the sample's optical density (OD) at 450nm with a micro plate reader.
- Mean negative control OD value  $\leq 0.1$  and positive control OD value  $\geq 0.8$ , the test is valid, otherwise the test is invalid.

- Cut-Off value (C.O.) = Mean negative control OD value + 0.10 (Calculated by 0.05 when Mean negative control OD value is  $\leq 0.05$ , calculated by actual value when Mean negative control OD value is  $> 0.05$ ).

#### Positive Results: Sample O.D value $\geq$ C.O.

Specimens giving an absorbance equal to or greater than the Cut-Off value are considered initially reactive, which indicates that Toxo IgM has probably been detected using Toxo IgM ELISA. All initially reactive specimens should be retested in duplicates using Toxo IgM ELISA before the final assay results interpretation. Repeatedly reactive specimens can be considered positive for Toxo IgM with Toxo IgM ELISA.

#### Negative Results: Sample OD value $<$ C.O

Specimens giving absorbance less than the Cut-Off value are negative for this assay, which indicates that no Toxo IgM has been detected with Toxo IgM ELISA, therefore the patient is probably not infected with Toxo and the blood does not contain Toxo IgM.

#### LIMITATIONS

- Positive results must be confirmed with another available method and interpreted in conjunction with the patient clinical information.
- Clinical diagnosis should not be established based on a single test result. It should integrate clinical and other laboratory data and findings.

#### PERFORMANCE CHARACTERISTICS

##### Specificity

A study of 216 individuals was tested with the ELISA kits and found that the specificity was 99.05%.

##### Sensitivity

Among 181 Toxo IgM confirmed were positive when tested with this ELISA, and 180 samples of which were detected with positive, the sensitivity was 99.45%.

##### Precision

###### Intra-assay

CV  $\leq 15\%$

Within-run precision has been determined by using 15 replicates of three specimens: a low positive, medium positive and a high positive.

###### Inter-assay

CV  $\leq 20\%$

Between-run precision has been determined by 3 independent assays on the same three specimens: a low positive, medium positive and a high positive. Three different lots of the Toxo IgM ELISA Test Kit have been tested using these specimens over a 5-day period.

##### Analytical specificity

Interferences are not observed up to a concentration of 1 mg/mL Acetaminophen, 0.2 mg/mL Gentistic Acid, 0.1 mg/mL Ascorbic Acid, 0.1 mg/ mL Acetosalisilyc Acid, 0.1 mg/mL Caffeine, 0.6 mg/mL Oxalic Acid, 2 mg/mL Bilirubin, 2 mg/mL Hemoglobin, and 1% Ethanol.

Rheumatoid factors do not interfere with the test.

Cross-Reactivity are not observed in Toxo IgG, Syphilis, HBsAg, HCV, RF and HCG positive specimens.

#### REFERENCES

1. Parasites – Toxoplasmosis (Toxoplasma infection) Disease". July 10, 2014. Archived from the original on 22 August 2015. Retrieved 22 August 2015.
2. Hunter, CA; Sibley, LD (November 2012). "Modulation of innate immunity by Toxoplasma gondii virulence effectors". *Nature Reviews Microbiology*. 10 (11): 766–78. doi:10.1038/nrmicro2858. PMC 3689224. PMID 23070557.
3. "Parasites – Toxoplasmosis (Toxoplasma infection) Epidemiology & Risk Factors". March 26, 2015. Archived from the original on 23 August 2015. Retrieved 22 August 2015.
4. Torgerson, Paul R; Mastroiacovo, Pierpaolo (2013). "The global burden of congenital Toxoplasmosis: a systematic review". *Bulletin of the World Health Organization*. 91 (7): 501–508. doi:10.2471/BLT.12.111732. ISSN 0042-9686. PMC 3699792. PMID 23825877.
5. Flegr J, Prandota J, Sovičková M, Israili ZH (March 2014). "Toxoplasmosis—a global threat. Correlation of latent Toxoplasmosis with specific disease burden in a set of 88 countries". *PLoS ONE*. 9 (3): e90203.

Bibcode:2014PLoS...990203F. doi:10.1371/journal.pone.0090203. PMC 3963851. PMID 24662942. Toxoplasmosis is becoming a global health hazard as it infects 30–50% of the world human population.

6. Jones JL, Parise ME, Fiore AE (2014). "Neglected parasitic infections in the United States: Toxoplasmosis". *American Journal of Tropical Medicine and Hygiene*. 90 (5): 794–9. doi:10.4269/ajtmh.13-0722. PMC 4015566. PMID 24808246.
7. Montoya JG (2002). "Laboratory diagnosis of Toxoplasma gondii infection and Toxoplasmosis". *The Journal of Infectious Diseases*. 185 Suppl 1: S73–82. doi:10.1086/338827. PMID 11865443.



ATLAS MEDICAL GmbH

Ludwig-Erhard Ring 3

15827 Blankenfelde-Mahlow

Germany

Tel: +49 - 33708 – 3550 30

Email: [Info@atlas-medical.com](mailto:Info@atlas-medical.com)

Website: [www.atlas-medical.com](http://www.atlas-medical.com)

PPI1530A01

Rev D (18.07.2023)

	Catalogue Number		Temperature limit
	In Vitro diagnostic medical device		Caution
	Contains sufficient for <n> tests and Relative size		Consult instructions for use (IFU)
	Batch code		Manufacturer
	Fragile, handle with care		Use-by date
	Manufacturer fax number		Do not use if package is damaged
	Manufacturer telephone number		Date of Manufacture
	Keep away from sunlight		Keep dry